Precision therapy. Personalized care.
We are passionate about targeted cancer care expertly tailored to meet patients’ personalized needs. We carefully designed the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® to empower physicians with full confidence to precisely and effectively treat cancer and enable patients to live healthy, high-quality lives.
IORT: Can a New Multidisciplinary Approach Make a Difference in Treating Brain Tumors?
Join us for a free virtual roundtable discussion featuring leading experts in Neuro-oncology who will share how intraoperative radiation therapy (IORT) is emerging as a multidisciplinary approach for the treatment of brain tumors.
Michael Howard, PhD DABMP RSODirector of Oncology Services, Chief of Medical Physics, Sarah Cannon Cancer Institute, Parkridge Medical Center, HCA HealthcareAlexey Krivoshapkin, PhDHead of Neurosurgery branch of Neurology and Neurosurgery School, MD, Professor, Neurosurgeon at the European Medical Center in Moscow, RussiaDr. Santosh Kesari MD, PhDDirector of Neuro-oncology Chair and Professor, Department of Translational Neurosciences at Saint John's Cancer Institute in Santa Monica, CA
From the Newsroom
April 5, 2022
iCAD Announces Additional Patients Treated Under GLIOX Trial and Continued Global Momentum for Xoft Intraoperative Radiation Therapy (IORT) for Brain, Rectal, Head and Neck Tumor Treatment
Medical City Plano, a HCA Healthcare Facility, becomes first in Texas to offer intraoperative radiation therapy with the advanced Xoft System to enhance patient care.
Discover the growing body of favorable clinical data supporting the use of electronic brachytherapy (eBx) in patients meeting specific selection criteria.
Discover our Advanced, Multi-Platform System
© Xoft, a subsidiary of iCAD, Inc. All rights reserved. Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are registered trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.